CASIRIVIMAB/IMDEVIMAB 120mg/ml+120mg/ml concentrate for solution for infusion EGIS
Chemical substance: casirivimab + imdevimab
ATC code: J06BD07 • Antiinfectives for systemic use | Immunoglobulins | Antiviral monoclonal antibodies
Active substance
Results for the substance casirivimab imdevimab
3 results
About this active substance
Casirivimab and imdevimab are monoclonal antibodies used for the treatment and prevention of COVID-19 in patients at high risk of developing severe disease. These antibodies work by binding to the spike protein of the SARS-CoV-2 virus, preventing it from entering human cells.
This combination is administered either as an intravenous infusion or subcutaneous injections, depending on the doctor's instructions. The treatment is most effective when given in the early stages of infection or as post-exposure prophylaxis.
Patients should be closely monitored during and after administration to detect potential adverse reactions, such as allergic reactions or hypersensitivity symptoms. It is important that the treatment is administered under medical supervision.
Side effects may include injection site reactions, fever, fatigue, headache, or, in rare cases, severe allergic reactions. Patients should inform their doctor of any unusual symptoms.
This combination is administered either as an intravenous infusion or subcutaneous injections, depending on the doctor's instructions. The treatment is most effective when given in the early stages of infection or as post-exposure prophylaxis.
Patients should be closely monitored during and after administration to detect potential adverse reactions, such as allergic reactions or hypersensitivity symptoms. It is important that the treatment is administered under medical supervision.
Side effects may include injection site reactions, fever, fatigue, headache, or, in rare cases, severe allergic reactions. Patients should inform their doctor of any unusual symptoms.
-
-
RONAPREVE 120mg/ml+120mg/ml solution for injection / infusion ROCHE
Chemical substance: casirivimab + imdevimab
ATC code: J06BD07 • Antiinfectives for systemic use | Immunoglobulins | Antiviral monoclonal antibodies
-
RONAPREVE 300mg+300mg solution for injection / infusion ROCHE
Chemical substance: casirivimab + imdevimab
ATC code: J06BD07 • Antiinfectives for systemic use | Immunoglobulins | Antiviral monoclonal antibodies